GlaxoSmithKline agrees drug discovery collaboration with Chiromics

GlaxoSmithKline has entered into a collaboration with Chiromics on a new drug discovery partnership utilising advanced technology.

The companies will seek to develop novel classes of small molecules against certain biological targets using Chiromics' cascade catalysis method, which it uses to assemble its compound collections.

Created by the MacMillan Laboratories at Princeton University, this technology allows complex and highly differentiated collections of molecules to be created, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.

Moreover, Chiromics' exclusive Chalis hit-recognition algorithm for affinity screening will also facilitate the overall process.

Dr David MacMillan, founder of Chiromics, said: "This collaboration further validates that our chemical technology and discovery platform is a potentially valuable gateway to a new set of small molecules for drug discovery."

Last month, it was announced that GlaxoSmithKline will be allying with Aeras to develop a new vaccine for tuberculosis.